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Background. Nitrosylcobalamin (NO-Cbl) is a chemotherapeutic pro-drug derived from vitamin B12 that preferentially
delivers nitric oxide (NO) to tumor cells, based upon increased receptor expression. NO-Cbl induces Apo2L/TRAIL-mediated
apoptosis and inhibits survival signaling in a variety of malignant cell lines. Chemotherapeutic agents often simultaneously
induce an apoptotic signal and activation of NF-kB, which has the undesired effect of promoting cell survival. The specific
aims of this study were to 1) measure the anti-tumor effects of NO-Cbl alone and in combination with conventional
chemotherapeutic agents, and to 2) examine the mechanism of action of NO-Cbl as a single agent and in combination
therapy. Methodology. Using anti-proliferative assays, electrophoretic mobility shift assay (EMSA), immunoblot analysis and
kinase assays, we demonstrate an increase in the effectiveness of chemotherapeutic agents in combination with NO-Cbl as
a result of suppressed NF-kB activation. Results. Eighteen chemotherapeutic agents were tested in combination with NO-
Cbl, in thirteen malignant cell lines, resulting in a synergistic anti-proliferative effect in 78% of the combinations tested.
NO-Cbl pre-treatment resulted in decreased NF-kB DNA binding activity, inhibition of IkB kinase (IKK) enzymatic activity,
decreased AKT activation, increased caspase-8 and PARP cleavage, and decreased cellular XIAP protein levels. Conclusion.
The use of NO-Cbl to inhibit survival signaling may enhance drug efficacy by preventing concomitant activation of NF-kB
or AKT.
Citation: Bauer JA, Lupica JA, Schmidt H, Morrison BH, Haney RM, et al (2007) Nitrosylcobalamin Potentiates the Anti-Neoplastic Effects of
Chemotherapeutic Agents via Suppression of Survival Signaling. PLoS ONE 2(12): e1313. doi:10.1371/journal.pone.0001313
INTRODUCTION
A major obstacle to conventional chemotherapy is the unwanted
activation of survival signaling which leads to acquired resistance
and decreased therapeutic efficacy. Nuclear factor kappa-B (NF-
kB)[1] and Akt [2] are critical mediators of cell survival that are
activated following chemotherapy.
NF-kB is a family of heterodimers: NF-kB1 (p50/p105), NF-
kB2 (p52/p100), REL, RELA (p65/NF-kB3) in mammals, Dosal,
Dif, and Relish in Drosophilia [3]. In its quiescent state, NF-kBi s
complexed to the inhibitor of kB( I kB) in the cytoplasm. Once
phosphorylated , IkB is ubiquitinated and targeted for proteolysis
as it remains complexed to NF-kB[4]. Within the proteosome IkB
is degraded, while NF-kB is not, allowing NF-kB to translocate to
the nucleus where it binds to NF-kB response elements which
activate transcription of target genes [5]. NF-kB activation is
mediated by kinase cascades that activate IkB kinase (IKK) which
is comprised of the subunits IKKa, IKKb, IKKc and function to
initiate the signal for degradation of IkB[3,6].
Constitutive activation of NF-kB has been implicated in the
development of chemo-resistance in several human carcinoma cell
lines[7–9]. Low dose doxorubicin can induce drug resistance in
cervical carcinoma cells[10]. Human breast cancer specimens
contain high levels of NF-kB/RelA indicating constitutive NF-kB
activation[11]. High levels of NF-kB and its downstream induced
anti-apoptotic genes, bcl-2 and bax correlated with poor response in
numerous breast cancer patients[12]. Constitutive NF-kB activity is
increasedincolorectalcancer[13] andeffectivetreatment isachieved
by inhibiting NF-kB[14]. Inhibitor of Kappa B Kinase (IKK), an
activator of NF-kB, has been shown to be constitutively active in
some prostate carcinoma cell lines[15]. Inhibition of NF-kB
increased the efficacy of a variety of chemotherapeutic agents
including paclitaxel, etoposide, doxorubicin, cisplatin, 5-FU, irino-
tecan, CPT-11, and camptothecin [16–20] thereby potentiating
apoptosis. Similarly, inhibition of AKT can enhance anti-tumor
activity of paclitaxel against cervical carcinomas[21].
Akt, a serine/threonine kinase that mediates survival signaling,
functions as an oncogene and is implicated in resistance to
chemotherapy[22]. AKT1 kinase was found to be elevated in the
majority of primary prostate, breast and ovarian carcinomas
examined and correlated with high grade and stage of disease[23].
AKT2 was up-regulated in human ovarian[24] and breast
Academic Editor: Elizabeth Grimm, The University of Texas M. D. Anderson
Cancer Center, United States of America
Received August 10, 2007; Accepted October 22, 2007; Published December 12,
2007
Copyright:  2007 Bauer et al. This is an open-access article distributed under
the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the
original author and source are credited.
Funding: This work was supported by Public Health Service grant CA095020 to
D.J.L. and CA84406 to J.A.D. from the National Cancer Institute and gifts from the
Mareb Foundation, the Reuter Foundation, and the Charles R. Jelm Foundation to
J.A.B.
Competing Interests: The authors have declared that no competing interests
exist.
* To whom correspondence should be addressed. E-mail: bauerj@ccf.org (JAB);
lindned@ccf.org (DJL)
. These authors contributed equally to this work.
PLoS ONE | www.plosone.org 1 December 2007 | Issue 12 | e1313carcinomas[25] and was associated with paclitaxel[26] and
cisplatin resistance[25]. In addition, decreased activation of
AKT via inhibition of phosphoinositide-3-kinase (PI3K) resulted
in increased apoptosis of ovarian cancer cells[27]. AKT
phosphorylates X-linked inhibitor of apoptosis (XIAP) thereby
promoting cell survival[28]. Thus, NF-kB and AKT-mediated
survival signaling limit the apoptotic-potential of chemotherapeu-
tic agents suggesting that inhibitors of these pathways can suppress
drug resistance and improve therapeutic efficacy.
We have previously demonstrated the anti-tumor activity of
nitrosylcobalamin (NO-Cbl) as a single agent and in combination
with biological therapies such as IFN-b[29] and Apo2L/
TRAIL[30]. NO-Cbl is a vitamin B12 based, nitric oxide donor,
that functions as a biological ‘‘Trojan Horse’’ targeting cancer cells
via vitamin B12 receptor (Transcobalamin II receptor,
TCIIR)[31,32] mediated uptake[29] similar to clinical studies
that target TCIIR in the detection of cancer[33,34].
We have previously shown that NO-Cbl suppressed Apo2L/
TRAIL- and TNF-a- mediated IKK activation with subsequent
decreased phosphorylation of IkBa and inhibition of NF-kB DNA
binding activity[30]. NO-Cbl sensitized Apo2L/TRAIL-resistant
cells to Apo2L/TRAIL-mediated cell death[30]. We have
determined that NO-Cbl mediated apoptosis caused in part via
activation of the death receptor 4 (DR4) by S-nitrosylation [35].
DR4 mediated apoptosis is tumor specific because Apo2L/TRAIL
is overexpressed on the surface of tumors but not on normal tissues
such as liver or kidney[36]. Thus, NO-Cbl is a promising
candidate to promote apoptosis and minimize toxicity in
combination chemotherapy. In the current study, we examined
whether NO-Cbl pre-treatment could potentiate the anti-tumor
effects of several chemotherapeutic agents.
RESULTS
Anti-proliferative effects of NO-Cbl and
chemotherapeutic agents in vitro
To test the hypothesis that NO-Cbl might potentiate the anti-
neoplastic effects of various chemotherapeutic agents, we mea-
sured antiproliferative effects in thirteen cell lines using 18
chemotherapeutic agents (Figure 1). We used the SRB antiprolif-
erative assay, which is utilized by the National Cancer Institute to
evaluate new chemotherapeutic agents[37]. Median effect analysis
characterized the interaction between NO-Cbl and the chemo-
therapeutic agents[38]. Cells were pre-treated with NO-Cbl for
16 h followed by the chemotherapeutic drugs for 80 h. Sequential
treatment of tumor cell lines resulted in synergistic antiproliferative
activity in 77.78% of the combinations tested, with a mean
combination index of 0.44 (95% CI=0.39 to 0.50). Antagonistic
responses were observed in 22.22% of combinations, with an
average combination index of 1.73 (95% CI=1.33 to 2.12).
NO-Cbl inhibits activation of NF-kBb y
chemotherapeutic agents
EMSA was utilized to examine the effects of NO-Cbl on NF-kB
activation by chemotherapeutic agents (Figure 2). We examined
four histologically distinct human tumor cell lines [A375
(melanoma), MCF-7 (breast carcinoma), SW480 (colon carcino-
ma), and OVCAR-3 (ovarian carcinoma)], assaying the effects of
multiple chemotherapeutic drugs. TNF-a was used as a positive
control for induction of NF-kB DNA binding activity. Specific
antibodies to NF-kB-p65 induced a supershift and confirmed the
presence of the p65/RelA component of NF-kB.
Figure 1. Effects of nitrosylcobalamin (NO-Cbl) and chemotherapeutic agents on the proliferation of A375 (melanoma), A549 (lung), ACHN
(renal), HeLa (cervical) HEY (ovarian), HT29 (colon), MCF-7 (breast), OC-2 and OC-3 (platinum and paclitaxel refractory ovarian), OVCAR-3
(ovarian), WM9 and WM3211 (melanoma), and P388 (murine leukemia). Cells were pre-treated with NO-Cbl for 16 h followed by addition of
chemotherapeutic agents for five days, and growth was measured by the colorimetric sulforhodamine B assay(37, 75). Data points represent the
combination index comparing low, medium, and high combinations of NO-Cbl and each chemotherapeutic agent (mean of eight replicates) to assess
synergy. Synergy between NO-Cbl and various chemotherapeutic agents was determined by median effect analysis(38), (combination index .1
indicates antagonism, =1 indicates additivity, and ,1 indicates synergy). The sequential treatment of NO-Cbl and chemotherapeutic drugs induced
synergistic antiproliferative activity in 77.7% of the combinations examined.
doi:10.1371/journal.pone.0001313.g001
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cell lines. NO-Cbl inhibited NF-kB DNA binding activity in A375
cells by 40.71% (95% CI=40.52% to 40.87%), MCF-7 cells by
46.99% (95% CI=46.41% to 47.64%), SW480 cells by 7.52%
(95% CI=5.71% to 9.14%), and OVCAR-3 cells by 40.13%
(95% CI=39.30% to 41.08%).
Cisplatin treatment resulted in low-level NF-kB activation in
A375 cells. NO-Cbl inhibited cisplatin-induced activation by
41.54% (95% CI=40.77% to 42.41%) in A375 cells. Cisplatin did
not activate NF-kB in OVCAR-3 cells.
5-FU activated NF-kB in each cell line treated. NO-Cbl inhibited
NF-kB activation in A375 cells by 6.89% (95% CI=6.43% to
7.28%), SW480 cells by 38.14% (95% CI=34.91% to 40.69%), and
OVCAR-3 cells by 18.34% (95% CI=17.90% to 18.72%).
Etoposide activated NF-kB in A375 and OVCAR-3 cells. Pre-
treatment with NO-Cbl inhibited NF-kB DNA binding activity by
29.70% (95% CI=28.79% to 30.69%) in A375 cells, and 30.37%
(95% CI=30.00% to 30.67%) in OVCAR-3 cells.
Paclitaxel treatment of MCF-7 and OVCAR-3 cells induced
NF-kB activation in both cell lines. NO-Cbl inhibited paclitaxel-
induced activation by 47.28% (95% CI=46.23% to 48.43%) and
43.40% (95% CI=42.48% to 44.47%) respectively, in MCF-7
and OVCAR-3 cells.
NO-Cbl effects IkB kinase activity
IkB kinase (IKK) mediates phosphorylation of IkBa, marking it for
eventual polyubiquitination and proteolysis thereby resulting in
NF-kB activation[39]. Hence, we examined the effect of NO-Cbl
upon IKK activity (Figure 3) using the same lysates used to assess
NF-kB DNA binding activity. NO-Cbl treatment reduced basal
IKK activity in all treatments, although IKK activity was not
noticeably increased in A375 cells following treatment with any of
the chemotherapeutic agents.
Doxorubicin activated IKK in MCF-7, SW480 and OVCAR-3
cells. NO-Cbl decreased IKK activity in MCF-7, SW480 and
OVCAR-3 cells by 41.70% (95% CI=39.65% to 44.47%),
45.22% (95% CI=41.43% to 50.07%) and 50.69% (95%
CI=48.39% to 53.57%), respectively.
Cisplatin treatment resulted in minor activation of IKK only in
OVCAR-3 cells. NO-Cbl was effective at inhibiting this activation
by 17.06% (95% CI=15.48% to 19.06%). 5-FU treatment
resulted in IKK activation in SW480 and OVCAR-3 cells. NO-
Cbl inhibited 5-FU induced IKK activation in SW480 cells by
18.85% (95% CI=17.20% to 21.05%), and OVCAR-3 cells by
34.12% (95% CI=31.21% to 37.74%). Paclitaxel did not activate
IKK in MCF-7 or OVCAR-3 cells. Treatment of OVCAR-3 cells
with etoposide resulted in IKK activation which was inhibited by
NO-Cbl by 71% (95% CI=70.22% to 71.96%).
Inhibition of AKT activation by NO-Cbl
Next we examined the role of the pro-survival protein AKT and
the effects of NO-Cbl on its activation (Figure 4), using the same
lysates utilized in the previous two experiments. In A375 cells,
phosphorylation of AKT was enhanced following treatment by
cisplatin, 5-FU and etoposide. NO-Cbl inhibited AKT activation
following cisplatin treatment by 51.24% (95% CI=50.73% to
51.73%), 5-FU by 42.82% (95% CI=39.84% to 47.26%), and
with etoposide by 46.85% (95% CI=44.00% to 49.32%).
Doxorubicin increased the phosphorylation of AKT in MCF-7
and SW480 cells which was inhibited by NO-Cbl by 83.77% (95%
CI=81.43% to 86.21%) and 52.60% (95% CI=49.62% to
55.04%), respectively. Treatment of MCF-7 cells with paclitaxel
resulted in increased phosphorylation of AKT which was inhibited
by 43.74% (95% CI=42.01% to 45.00%) following NO-Cbl.
Treatment of SW480 cells with 5-FU increased AKT activation
which was inhibited by NO-Cbl by 32.50% (95% CI=31.28% to
33.61%). Although increased phosphorylation of AKT did not
occur with any of the chemotherapeutic agents in OVCAR-3 cells,
which exhibited a high basal level of phosphorylated AKT, NO-
Cbl reduced the high basal AKT phosphorylation levels.
XIAP expression is decreased with NO-Cbl treatment
X-linked mammalian inhibitor of apoptosis (XIAP), one of the
most potent inhibitors of apoptosis, is a NF-kB-induced gene[40].
Hence we examined effects of NO-Cbl upon downstream gene
products induced by NF-kB (Figure 5).
Consistent with AKT phosphorylation in A375 cells, XIAP
protein expression was enhanced following doxorubicin, cisplatin,
5-FU, and etoposide treatment. NO-Cbl blunted XIAP expression
by 20.12% (95% CI=14.64% to 23.79%) with doxorubicin,
19.40% (95% CI=17.06% to 22.00%) with cisplatin, 21.12%
(95% CI=20.89% to 21.31%) with 5-FU, and 18.62% (95%
CI=17.57% to 20.09%) with etoposide.
In addition, doxorubicin increased XIAP expression in MCF-7,
SW480, and OVCAR-3 cells; expression was inhibited with NO-
Cbl treatment by 44.96% (95% CI=39.66% to 47.85%), 12.16%
(95% CI=10.57% to 13.79%), and 64.90% (95% CI=60.46% to
Figure 2. Electrophoretic Mobility Shift Assay (EMSA): NF-kB DNA
binding activity. Pretreatment of A375 (melanoma), MCF-7 (breast
carcinoma), SW480 (colon carcinoma) and OVCAR-3 (ovarian carcinoma)
cells with NO-Cbl (300 mM, 16 h) inhibited the NF-kB DNA binding
activity induced by doxorubicin (20 mM, 4 h) or cisplatin (20 mM, 1 h) or
5 flurouracil (5-FU, 100 mM, 5 h) or etoposide (20 mM, 4 h) or paclitaxel
(20 mM, 5 h). TNF-a (15 min) stimulation served as a positive control of
NF-kB activation (T). Incubation of TNF-a treated lysates with anti-NF-kB
p65 antibody resulted in supershift (SS) of the NF-kB complex (Ta). An
irrelevant antibody was incubated with TNF-a treated lysates which did
not result in a supershift (Tx).
doi:10.1371/journal.pone.0001313.g002
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in SW480 cells which was inhibited with NO-Cbl by 13.66% (95%
CI=11.87% to 15.75%). NO-Cbl treatment inhibited basal XIAP
expression when combined with every chemotherapeutic agent in
all cell lines examined.
Effect of NO-Cbl on mediators of apoptosis
A375 cells were stimulated with doxorubicin, followed by assessment
of AKT phosphorylation, XIAP expression, and caspase-8 and
PARP cleavage. (Figure 6a). NO-Cbl inhibited doxorubicin-
mediated AKT activation at all time points, resulting in reduction
of 85.73% (95% CI=85.26% to 86.24%) at 8 h, 94.05% (95%
CI=92.44% to 96.02%) at 12 h, 60.94% (95% CI=58.93% to
63.73%) at 16 h, and completely abrogated the signal at 24 h. In
addition, degradation of XIAP was enhanced when NO-Cbl was
combined with doxorubicin; this inhibition was 82.94% (95%
CI=81.27% to 84.14%) at 8 h, 49.36% (95% CI=41.51% to
58.74%) at 12 h, 64.67% (95% CI=60.68% to 67.69%) at 16 h,
and 35.81% (95% CI=33.93% to 36.54%) at 24 h.
Concordantly, caspase-8 activity was enhanced when NO-Cbl
was combined with doxorubicin at 8, 12, 16 and 24 h by 41.39%
(95% CI=27.98% to 47.95%), 36.82% (95% CI=32.79% to
39.87%), 17.54% (95% CI=12.22% to 23.98%), and 25.28%
(95% CI=7.88% to 34.92%), respectively. PARP cleavage was
increased at all time points following treatment with NO-Cbl and
doxorubicin. NO-Cbl enhanced the cleavage of PARP by 82.94%
(95% CI=81.27% to 84.14%) at 8 h, 49.36% (95% CI=41.51%
to 58.74%) at 12 h, 64.67% (95% CI=60.68% to 67.69%) at
16 h, and by 35.81% (95% CI=33.93% to 36.54%) at 24 h.
Next, we examined the expression of XIAP in OVCAR-3 cells
treated with etoposide and NO-Cbl (Figure 6b). Expression of
XIAP protein, normally induced by etoposide, was reduced by
NO-Cbl at 8, 12, and 16 h by 92.82% (95% CI=89.60% to
97.78%), 78.57% (95% CI=70.12% to 89.26%), and 98.59%
(95% CI=96.71% to 100%), respectively. After 24 h of NO-Cbl
treatment, XIAP protein was undetectable.
Anti-tumor effects of NO-Cbl and chemotherapeutic
agents in vivo
In vitro combination therapy with NO-Cbl on tumor cells in culture
exhibited positive effects in inhibiting cell proliferation and decreas-
ing cell survival signaling (Figs. 1–6). To test drug combinations in
vivo, subcutaneous NIH-OVCAR-3 xenografts were established in
athymic nude mice. Daily drug treatments began on day 2 after cell
inoculation, at which time tumors were both visible and palpable
(Figure 7a). After 25 days, the tumors from mice treated with NO-
Cbl were reduced in volume by 66.94% (95% CI=60.90% to
69.81%; P=0.00068) compared to controls. Tumors from mice
treatedwithetoposideweresmallerby27.30%(95%CI=19.70%to
30.90%; P=0.14099) compared to control tumors. Mice receiving
the combination of NO-Cbl and etoposide displayed tumors that
were inhibited by 99.01% (95% CI=98.48% to 100.12%;
P=.000012) compared to controls. In two mice, tumors disappeared
completely and did not recur 60 days after treatment cessation.
Figure 3. IkB kinase (IKK) activity. IKK activity was assessed using recombinant GST-IkBa(1-54) and c
32P-ATP as substrates. The phosphorylated
GST fusion protein was detected by autoradiography. IKK activity was determined in cells that were pre-treated with NO-Cbl (300 mM, 16 h) followed
by doxorubicin (20 mM, 4 h) or cisplatin (20 mM, 1 h) or 5 flurouracil (5-FU, 100 mM, 5 h) or etoposide (20 mM, 4 h) or paclitaxel (20 mM, 5 h). Anti-b-
actin antibody was used as an irrelevant antibody control for immunoprecipitation and yielded no signal. After exposure to film, the gel was stained
with Coomassie blue to visualize total protein and demonstrated equal loading of the GST-IkBa(1-54) substrate. The same cell extracts were probed
for total IKK by immunoblot analysis and demonstrated equal loading of IKK.
doi:10.1371/journal.pone.0001313.g003
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inoculated into the peritoneal cavities of DBA/2 mice. Daily drug
treatments began on day 2 following inoculation (Figure 7b).
Untreated animals died by day 14. NO-Cbl treated animals
survived until day 21. Doxorubicin treated animals survived until
day 33. Combination drug treatment was discontinued on day 40
and resulted in 60% survival, monitored through day 90. Logrank
analysis determined P,0.001 comparing Kaplan Meier survival
curves.
DISCUSSION
Nitric oxide (NO) is a ubiquitous multi-faceted signaling molecule
critical to many physiological and pathological processes[41]. A
comprehensive review by Mocellin et al. details the use of NO
Figure 4. Western blot analysis of phospho-AKT. Cells were pre-treated with NO-Cbl (300 mM, 16 h) followed by doxorubicin (20 mM, 4 h) or
cisplatin (20 mM, 1 h) or 5 flurouracil (5-FU, 100 mM, 5 h) or etoposide (20 mM, 4 h) or paclitaxel (20 mM, 5 h). Whole cell lysates were probed with
anti-phospho-AKT and then re-probed with anti-AKT (unphosphorylated) which served as a loading control.
doi:10.1371/journal.pone.0001313.g004
Figure 5. Western blot analysis of XIAP. Cells were pre-treated with NO-Cbl (300 mM, 16 h) followed by doxorubicin (20 mM, 4 h) or cisplatin (20 mM,
1 h) or 5 flurouracil (5-FU, 100 mM, 5 h) or etoposide (20 mM, 4 h) or paclitaxel (20 mM, 5 h). XIAP protein levels were determined in whole cell lysates.
GAPDH was used as a loading control.
doi:10.1371/journal.pone.0001313.g005
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donors and apoptosis often seems paradoxic and depends upon cell
type, site of delivery, and NO concentration. However, it is widely
accepted that high levels of NO (.1 mM) can activate the extrinsic
pathway of programmed cell death via protein nitrosylation[35,43]
and can also activate the intrinsic pathway via oxidative stress and
cytochrome c release[44]. Most conventional NO donors, especially
those with short half-lives such as GTN, SNP and SNAP, induce
significant toxicity to normal cells due to rapid NO release in
biological fluids[45,46], a drawback to their use.
A major advantage of the pro-drug NO-Cbl is its tumor-specific
accumulation due to higher transcobalamin receptor (TCII-R)
expression in tumor cells compared to normal tissues[29].
Cobalamin (Cbl) is avidly taken up by tumor cells relative to
most normal tissues[34,47,48] Unlike other donors, NO-Cbl
preferentially releases NO inside the cell, and therefore minimizes
systemic toxicity due to high plasma NO concentration. By taking
advantage of the ‘‘Trojan Horse’’ properties of NO-Cbl, side
effects such as vasodilation can be minimized. We have not
observed hypotension, bone marrow suppression or abnormal liver
or kidney function in our rodent or canine studies following acute
or chronic NO-Cbl administration (data not shown).
NO inhibits survival signaling via inhibition of NF-kB [49,50]
and AKT [51], both well characterized mediators of cell survival.
A recent review by Nakanishi and Toi implicates NF-kB activation
as a major contributor to lowering the apoptotic efficacy of
chemotherapeutic agents and increasing drug resistance[52].
The activation of NF-kB is a highly complex process. There are
cell type-specific variations in NF-kB activation that differ between
cell lines as well as activation differences among known NF-kB-
activators. Taxol treatment of pancreatic cancer cell lines induces
formation of several different NF-kB/IkB complexes, suggesting
the presence of multiple up-stream activators of NF-kB[53]. UV-
induced DNA damage in HeLa cells is characterized by IKK-
independent activation of NF-kB at early time points (30 min) and
IKK-dependent activation at later times (15–20 h)[54]. Doxoru-
bicin initiates phosphoinositide-3-kinase (PI3K)-mediated degra-
dation of IkB that is independent of the IKK signalosome[55].
Conversely, both PI3K and AKT can mediate NF-kB activation
via phosphorylation of threonine 23 of IKKa, leading to NF-kB
activation[56]. In comparison, AKT required IKK in order to
activate NF-kB[57], specifically IKKb[58]. In addition, AKT
potentiates the effects of gemcitabine and paclitaxel in pancreatic
cancer possibly via NF-kB activation[59]. Similarly, AKT can
transiently bind and activate IKK following stimulation with
platelet-derived growth factor (PDGF)[60]. In melanoma, AKT
may activate NF-kB in an IKK-independent fashion[61] possibly
mediated by MAPK[62]. Undoubtedly, the complex nature of
NF-kB activation can be as paradoxic as the cellular actions of
NO.
Figure 6. Western blot analysis of mediators of apoptosis. A, Time course analysis of A375 cells pre-treated with NO-Cbl (300 mM, 16 h) followed by
doxorubicin (20 mM, 4 h). Phospho-AKT, XIAP, caspase-8 and PARP immunoblots were performed on whole cell lysates. Note that caspase-8 and PARP
cleavage were maximal with combination treatment at all time points. Degradation of XIAP was increased following combination treatment at all
time points. B, OVCAR-3 cells were pre-treated with NO-Cbl (300 mM, 16 h) followed by etoposide (20 mM, 4 h). XIAP protein levels were determined.
GAPDH was used as a loading control.
doi:10.1371/journal.pone.0001313.g006
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Cbl, irrespective of the survival pathways induced by a variety of
chemotherapeutic agents. We demonstrate increased NF-kB
DNA binding induced by almost every chemotherapeutic agent
across all cell lines. Doxorubicin, etoposide, and paclitaxel
induced NF-kB activation in all cell lines examined (Figure 2).
Interestingly, A375 cells had greater constitutive IKK activation
compared to MCF-7, SW480, and OVCAR-3 cells, and IKK
activity in A375 cells was not noticeably enhanced by any
chemotherapeutic agent (Figure 3). Yet, treatment of A375 cells
with NO-Cbl reduced basal IKK activity. The absence of
increased IKK activity in A375 cells following chemotherapeutic
drug treatment may be attributed to: 1) differences in the kinetics
of activation of IKK vs. NF-kB, and 2) preferential phosphory-
lation of the GST-IkBa(1-54) substrate by IKK-b rather than
IKK-a [63]. These factors may result in understated IKK-a
contributions to activation using the current kinase assay.
Admittedly, IKK-a may play a more dominant role in NF-kB
activation as compared to IKK-b mediated NF-kB activation in
A375 cells, but this topic is ancillary to the conclusion of this
study. The key observation is that where NF-kB is activated, NO-
Cbl inhibits the activation and furthermore, in activation
pathways that clearly utilize IKK to trigger NF-kB activation,
NO-Cbl treatment inhibits IKK activity.
Figure 7. Effects of NO-Cbl and chemotherapeutic agents in vivo. A, NCR male athymic nude (nu/nu) mice (n=10 per group) were injected
subcutaneously (s.c.) with 2610
6 NIH-OVCAR-3 cells. Daily drug treatments of control (PBS), NO-Cbl (150 mg/kg, s.c.), etoposide (2 mg/kg, s.c.), and
the combination began on day 2 following inoculation. Tumor volume was measured every other day. Points represent the mean tumor
volume695% CI. B, Kaplan-Meir survival curve. DBA/2 male mice (n=5) were inoculated intraperitoneally (i.p.) with 10
5 P388 murine leukemia cells.
NO-Cbl was given twice daily (165 mg/kg, i.p.) and doxorubicin (4 mg/kg, i.p.) was administered once weekly, starting on day 2. Treatment in the
combination group ceased on day 40 and the animals continued to be monitored for ninety days. Significance comparing the survival of groups was
calculated using the logrank test.
doi:10.1371/journal.pone.0001313.g007
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etoposide in A375 cells. NO-Cbl markedly reduced AKT
phosphorylation following all treatments (Figure 4). Thus, AKT
may be involved in NF-kB activation, independent of IKK, as
previously reported [61]. This may also explain activation of NF-
kB in MCF-7 cells following treatment by paclitaxel, accompanied
by AKT activation in the absence of IKK activation (Figure 4).
Alternatively, AKT and IKK may act in concert to activate NF-kB
[60]. In OVCAR-3 cells, AKT was not activated by any
chemotherapeutic agent whereas IKK activation was induced by
doxorubicin, etoposide, cisplatin, and 5-FU, suggesting IKK-
dependent activation in these cells (Figure 4). Our results with
paclitaxel are in agreement with results obtained by others in
ovarian cancer cells using paclitaxel [64]. Clearly, NF-kB signaling
is a complex process involving several pathways that provide
diverse control points resulting in a balance between apoptosis and
survival.
NO-Cbl inhibited expression of a NF-kB-induced survival
factor, namely X-linked inhibitor of apoptosis (XIAP) (Figure 5),
consistent with other studies in which S-nitrosoglutathione
(GSNO) inhibited XIAP expression[65]. Our data suggest that
the inhibitory effects of NO-Cbl on XIAP are post-translational as
well as transcriptional (Figure 5). The increase in caspase-8
activation, PARP cleavage and XIAP degradation are consistent
with the synergistic anti-proliferative effects of NO-Cbl (Figure 6)
and provide further evidence as to the chemopotentiating effects of
NO-Cbl. Elimination of OVCAR-3 and P388 tumors in vivo
(Figure 7) is consistent with the antiproliferative synergy observed
in vitro.
We are continuing to study the mechanism by which NO-Cbl
inhibits NF-kB activation. This likely involves S-nitrosylation [66].
Prostaglandins (PGA1 and 15dPGJ2) inhibit IKK by covalently
modifying a critical cysteine residue (C179) within the activation
loop [67]. S-nitrosylation of IKK-b leads to its inactivation[68]. In
addition, the NO donor SNAP has been shown to inhibit IKK-
b[69] as well as suppress AKT activation[51]. Also, inactivation of
AKT can result from S-nitrosylation and may be involved in
insulin resistance[70]. Alternatively or in addition, both IKK-c
and XIAP contain zinc fingers which are known targets for
nitrosylation [71]. Others have shown that NO can inhibit NF-kB
by direct S-nitrosylation of the DNA binding subunits [49,50,72]
or tyrosine nitration[73].
Therefore, NO-Cbl likely nitrosylates redox-sensitive residues in
its target proteins, causing inhibition of NF-kB-mediated survival
signaling and this appears to also be the case with AKT-mediated
survival signaling. We have shown that NO-Cbl maximizes the
anti-tumor effectiveness of primary chemotherapeutic agents. The
use of NO-Cbl to inhibit survival signaling may prevent drug
resistance, a common occurrence in multiple cycle chemotherapy,
and may improve response rates and enhance drug efficacy.
MATERIALS AND METHODS
Synthesis of Nitrosylcobalamin
Nitrosylcobalamin was synthesized as previously described[74].
Hydroxocobalamin (vitamin B12a) acetate (Hebei Huarong
Pharmaceutical Co, Hebei Province, China) was dissolved in
dichloromethane (OmniSolv, EMD Chemicals, Gibbstown, NJ)
and exposed to CP grade NO gas (Praxair, Wickliff, OH) at 75 psi.
The reaction proceeds in a closed system within a high-pressure
stainless steel reactor (Parr Instrument Co, Moline, IL). The
system was purged daily and evacuated prior to NO exposure. The
NO gas was scrubbed prior to entering the system using a stainless
steel cylinder (Midwest Process Controls, Bay Village, OH)
containing NaOH pellets. The solid NO-Cbl product was
collected following rotary evaporation of the solvent and stored
under argon at 280uC prior to use.
Cell Culture and Cytokine treatments
Human tumor cell lines (ATCC, Manassas, VA) were grown in
RPMI 1640 and Dulbecco’s modified Eagle medium as appro-
priate (DMEM, Cellgro, Mediatech Herndon, VA) supplemented
with 10% fetal bovine serum (FBS, Mediatech) and 1% Antibiotic-
Antimycotic (GIBCO BRL, Invitrogen, Carlsbad, CA) according
to ATCC recommendations. Cells were maintained in 5% CO2 at
37uC in a humidified incubator. Cells were confirmed as
mycoplasma free using a commercially available kit (MycoAlert,
Cambrex Corporation, East Rutherford, NJ).
Sulforhodamine B Cell Growth Assay
Cells were harvested with 0.5% trypsin/0.53 mM EDTA, washed
with PBS and resuspended in media containing 10% FBS. Cells
were plated in 96-well plates in 0.2 mL aliquots containing 2,000
cells. Cells were allowed to adhere to the plate for 4 h and then
NO-Cbl was added in different dilutions to the assay plate.
Replicates of eight were performed for each treatment. After 16 h,
chemotherapeutic agents were added at different concentrations.
Growth was monitored by the sulforhodamine B (SRB, Sigma
Chemical, St. Louis, MO) colorimetric assay[37,75]. After 80 h
growth, the medium was removed, and cells were fixed with 10%
trichloroacetic acid and stained with SRB. Bound dye was eluted
from cells with 10 mM TRIS (pH 10.5) and absorbance was
measured at 570 nm using a Lab Systems Multiskan RC 96-well
plate reader (Lab Systems Multiscan RC, Thermo Lab Systems,
Franklin, MA). To quantify growth of the cells, experimental
absorbance values (Aexp) were compared with initial absorbance
readings representing the starting cell numbers (Aini). To
determine the starting cell number, an additional 96-well plate
was seeded with cells and fixed at the beginning of the experiment.
The absorbances derived from the initial plate and from the
untreated cells at the end of the growth period (Afin) were defined
as 0% and 100% growth, respectively. The percentage control
growth (100%6[Aexp–Aini]/[Afin–Aini]) was expressed as a per-
centage of untreated controls.
In vivo experiments
Five week-old NCR male athymic nude homozygous (nu/nu) mice
(Taconic, Germantown, NY) were inoculated with NIH-OVCAR-
3 tumors. There were four experimental groups (untreated, single
agents, and the combination), n=10. Tumor cells (2610
6) were
inoculated into flanks in the mid-axillary line. NO-Cbl was given
once daily (150 mg/kg, s.c.) and etoposide (2 mg/kg, s.c.) was
administered once weekly, starting on day 2. Tumor volume was
measured three times a week using the formula for a prolate
spheroid: (4/3) pab
2 where 2a=major axis, 2b=minor axis.
Formalin-fixed sections were processed by the Cleveland Clinic
Histology Core. Sections were stained with hematoxylin and eosin
and evaluated for pathologic changes in a blinded fashion. For
syngeneic studies, five week-old DBA/2 male mice (Taconic) were
inoculated with P388 murine leukemia cells. There were four
experimental groups (untreated, single agents, and the combina-
tion), n=10. Tumor cells (10
5) were inoculated i.p.. NO-Cbl was
given twice daily (165 mg/kg, i.p.) and doxorubicin (4 mg/kg, i.p.)
was administered once weekly, starting on day 2. Animals were
monitored for ninety days. The Institutional Animal Care and Use
Committee at the Cleveland Clinic Foundation approved all
procedures for animal experimentation.
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Cells were pre-treated with NO-Cbl (300 mM) for 16 h followed
by doxorubicin (20 mM, 4 h), cisplatin (20 mM, 1 h), 5 flurouracil
(5-FU, 100 mM, 5 h), etoposide (20 mM, 4 h), or paclitaxel
(20 mM, 5 h). As a positive control for NF-kB induction, cells
were treated with TNF-a (20 ng/mL, 15 min). Whole cell lysates
were prepared in 16 high salt lysis buffer (20 mM HEPES,
400 mM NaCl, 25 mM b-glycerol phosphate, 25 mM NaF,
10 mM, para-nitrophenyl phosphate (PNPP), 10% glycerol,
0.5 mM NaOrthovanadate, 1mM PMSF, 0.5% NP40 and 16
protease inhibitor cocktail set I (Calbiochem) and 16phosphatase
inhibitor cocktail set II (Calbiochem) for subsequent immunoblot-
ting studies. Total cell protein (80 mg per sample) was resolved by
electrophoresis on a 10% Bis-TRIS gel (Criterion, Bio-Rad,
Hercules, CA) resolved at 160 V for 1 hour and transferred to a
PVDF membrane (Immobilon-P, Millipore, Bedford, MA) with
the use of a wet transfer apparatus (Bio-Rad) for 30 min at 100 V .
The membranes were incubated in blocking buffer (Starting Block
T20, Pierce, Rockford, IL) for 1 h at room temperature and then
incubated overnight with primary antibody [anti-phospho-AKT
(Ser473) 1:1000, Cell Signaling, Boston, MA; anti-AKT 1:1000,
Cell Signaling; anti-XIAP, 1:250-2000, BD Biosciences, San Jose
CA; anti-Caspase-8 (1C12) 1:1000 Cell Signaling; anti-PARP
1:1000, Cell Signaling] diluted in Starting Block. After washing in
16 TBST (USB Corp, Cleveland, OH) membranes were
incubated with horseradish peroxidase-conjugated goat secondary
antibodies (Biorad) diluted in Starting Block for 1 h at room
temperature. The protein bands were visualized by enhanced
chemiluminescence (SuperSignal West Pico chemiluminescent
substrate, Pierce). Antibodies against glyceraldehyde-3-phosphate
dehydrogenase (Trevigen, Gaithersburg, MD) were used to ensure
equal loading.
Electrophoretic mobility shift assay (EMSA)
Cells were pre-treated with NO-Cbl (300 mM) for 16 h followed
by doxorubicin (20 mM, 4 h) or cisplatin (20 mM, 1 h) or 5
flurouracil (5-FU, 100 mM, 5 h) or etoposide (20 mM, 4 h) or
paclitaxel (20 mM, 5 h). As a positive control for NF-kB induction,
cells were treated with TNF-a (20 ng/mL, 15 min). Plates were
washed three times with ice-cold 16DPBS (Cellgro, Mediatech).
Cells were scraped from plates and resuspended in 16 high salt
lysis buffer as above. The lysates were transferred to pre-chilled
microcentrifuge tubes and incubated at 4uC using a vortex for
30 min followed by centrifugation at 20,000g for 15 min. Samples
were snap frozen with liquid nitrogen and stored at 270uC until
needed. Supernatants were transferred to fresh tubes and protein
concentrations were assessed using the Bradford method (Bio-
RAD protein assay, BioRad, Hercules, CA). We used a
commercially available consensus binding site for NFkB/c-Rel
homodimeric and heterodimeric complexes as a probe to assess
DNA binding activity. The NF-kB consensus binding sequence
(59AGTTGAGGCGACTTTCCCAGGC 39) (sc-2505: Santa
Cruz Biotechnology, Santa Cruz, CA) was end-labeled with
c
32P-dATP (3000 Ci/mol, Perkin Elmer, Boston MA), using T4
polynucleotide kinase (Roche, Indianapolis, IN). DNA binding
reactions were performed in 28 mL reaction volume for 30 min on
ice containing 20 mg protein, 100 mM HEPES, 3.0 mM EDTA,
50% glycerol, 3 mM DTT, 25 mM MgCl2, 20 mM TRIS,
pH 7.90, 5 ug Poly [d(I-C)] and labeled probe. Complexes were
separated from the free probe on 6% non-denaturing polyacryl-
amide gels in 0.56TBE buffer at 195 V for 2 h. Gels were dried
and exposed to film. To verify that the band shifts were comprised
of NF-kB, lysates from cells that were stimulated by TNF-a
(20 ng/mL, 15 min) were incubated with anti-NF-kB p65
antibody (100 ng/mL, Zymed, S. San Francisco, CA).
IkB kinase (IKK) assay
Whole cell extracts (200 mg) treated as above were supplemented
with 150 mL of Buffer A (20 mM Hepes, pH 7.9, 20 mM beta-
glycerophosphate, 10 mM NaF, 0.1 mM orthovanadate, 5 mM
para-nitrophenyl phosphate (PNPP), 10 mM 2-mercaptoethanol
(BME), 0.5 mM PMSF, and protease cocktail), 2 mL normal rabbit
serum (NRS), and mixed by rotation at 4uC for 1 h as previously
described[76]. A 50% slurry of Protein G Sepharose (80 mL)
(Amersham-Pharmacia, Piscataway, NJ) prepared in Buffer A
(without BME or PMSF) was added and mixed by rotation at 4uC
for 1 h. Protein G Sepharose was removed by centrifugation at
800g for 1 min and discarded. Anti-IKKa monoclonal antibody
(0.5 mg, BD-Pharmingen, San Diego, CA), or anti-HA epitope
antibody (Covance, Berkeley, CA) was added to the supernatant
and mixed by rotation at 4uC for 2 h. A 50% slurry of Protein G
Sepharose (60 mL) prepared in Buffer C (Buffer A plus 50 mM
NaCl and 10 mM MgCl2, without BME and PMSF) was added
and mixed by rotation in the cold for 30 min. Protein G
immunopellets were collected by centrifugation at 800 g for
30 sec, washed 3 times with Buffer B (Buffer A plus 250 mM
NaCl), and once with Buffer C (Buffer A plus 50 mM NaCl and
10 mM MgCl2). Immunopellets were re-suspended in 30 mL
kinase buffer with 0.1 mM orthovanadate, 50 mM unlabeled ATP,
5 mCi c
32P-ATP, 2 mM DTT, and 2 mg of recombinant GST-
IkBa1-54[39] and incubated at 30uC for 30 min. Reactions were
stopped by the addition of 15 mL4 6SDS-PAGE loading buffer
(200 mM Tris-HCl, pH 6.8, 8% SDS, 40% glycerol, 0.2% 2-
mercaptoethanol), heated at 95uC for 10 min, and resolved by
SDS-PAGE on a 12% acrylamide gel by standard procedures.
Gels were rinsed, stained with Bio-Safe Coomassie (BioRad,
Hercules, CA) to visualize protein bands, rinsed, photographed
then dried and exposed to Kodak BioMax MR film (Eastman
Kodak Co., Rochester, NY) to detect substrate phosphorylation.
IKK activation was quantified by PhosphorImage analysis on a
Storm-840 imager using Image Quant v 5.2 software (Molecular
Dynamics, Amersham Biosciences, Piscataway, NJ).
Statistical Analysis
Median effect analysis was used to characterize the interaction
between NO-Cbl and various chemotherapeutic agents[38]. A
combination index .1 indicates antagonism, =1 indicates
additivity, and ,1 indicates synergy. Unless otherwise stated,
results are expressed as means with 95% confidence intervals (95%
CI). Differences in mean tumor volume between groups were
compared using the unpaired two-tailed Student’s t test, using a
pooled estimator of variance, to determine statistical significance
using Sigma Plot 10.0 (SPSS, Chicago, IL). The logrank test was
used to calculate the significance of the Kaplan Meir survival
curve. The experimental design utilized the same set of cell lysates
for Figures 2-5, and the data was expressed as means (n=3).
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